‡Centro de Biología Molecular Severo Ochoa (CSIC-UAM), 28049 Madrid, Spain.
§Faculty of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel.
Mol Cell Proteomics. 2019 Aug;18(8):1491-1510. doi: 10.1074/mcp.RA119.001515. Epub 2019 May 15.
The endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 trim peptides to be loaded onto HLA molecules, including the main risk factor for Behçet's disease HLA-B51. ERAP1 is also a risk factor among HLA-B51-positive individuals, whereas no association is known with ERAP2. This study addressed the mutual relationships between both enzymes in the processing of an HLA-bound peptidome, interrogating their differential association with Behçet's disease. CRISPR/Cas9 was used to generate knock outs of ERAP1, ERAP2 or both from transfectant 721.221-HLA-B51:01 cells. The surface expression of HLA-B51 was reduced in all cases. The effects of depleting each or both enzymes on the B51:01 peptidome were analyzed by quantitative label-free mass spectrometry. Substantial quantitative alterations of peptide length, subpeptidome balance, N-terminal residue usage, affinity and presentation of noncanonical ligands were observed. These effects were often different in the presence or absence of the other enzyme, revealing their mutual dependence. In the absence of ERAP1, ERAP2 showed similar and significant processing of B51:01 ligands, indicating functional redundancy. The high overlap between the peptidomes of wildtype and double KO cells indicates that a large majority of B51:01 ligands are present in the ER even in the absence of ERAP1/ERAP2. These results indicate that both enzymes have distinct, but complementary and partially redundant effects on the B51:01 peptidome, leading to its optimization and maximal surface expression. The distinct effects of both enzymes on the HLA-B51 peptidome provide a basis for their differential association with Behçet's disease and suggest a pathogenetic role of the B51:01 peptidome.
内质网氨肽酶 ERAP1 和 ERAP2 修剪要加载到 HLA 分子上的肽,包括 Behçet 病的主要风险因素 HLA-B51。ERAP1 也是 HLA-B51 阳性个体的风险因素,而与 ERAP2 无关。本研究探讨了两种酶在 HLA 结合肽组加工过程中的相互关系,探讨了它们与 Behçet 病的差异关联。使用 CRISPR/Cas9 从转染的 721.221-HLA-B51:01 细胞中生成 ERAP1、ERAP2 或两者的敲除。在所有情况下,HLA-B51 的表面表达均降低。通过定量无标记质谱分析,研究了耗尽每种或两种酶对 B51:01 肽组的影响。观察到肽长度、亚肽组平衡、N 末端残基使用、非经典配体的亲和力和呈递的大量定量变化。这些影响在存在或不存在另一种酶时往往不同,揭示了它们的相互依赖性。在缺乏 ERAP1 的情况下,ERAP2 对 B51:01 配体的处理表现出相似且显著的作用,表明存在功能冗余。野生型和双 KO 细胞的肽组之间存在高度重叠,表明即使在缺乏 ERAP1/ERAP2 的情况下,也有很大一部分 B51:01 配体存在于内质网中。这些结果表明,两种酶对 B51:01 肽组具有不同但互补且部分冗余的作用,从而优化和最大程度地表达其表面。两种酶对 HLA-B51 肽组的不同作用为它们与 Behçet 病的差异关联提供了基础,并提示 B51:01 肽组在发病机制中的作用。